Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 62
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 26
Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates
Magdi T. Abdelhamid, Al-Hassan Soliman Wadan, Hosam A. Saad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 4
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 16
Homogeneous multi-payload antibody–drug conjugates
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 16
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
Meiting Chen, Riqing Huang, R.C. Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 8, pp. e957-e966
Open Access | Times Cited: 14
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 12
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 10
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present
Jacob Naman, Nihar Shah, Benjamin Heyman
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1711-1711
Open Access | Times Cited: 1
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
X. Shi, Kai Tang, Quanbin Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Advancements in antibody-drug conjugates as cancer therapeutics
Jung Yin Fong, Zhixin Phuna, D. Chong, et al.
Journal of the National Cancer Center (2025)
Open Access | Times Cited: 1
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
Liliana Ascione, Edoardo Crimini, Dario Trapani, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. 944-960
Open Access | Times Cited: 18
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popović, Tajana Silovski, Marija Križić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8206-8206
Open Access | Times Cited: 17
Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 208-224
Open Access | Times Cited: 8
Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms
Ronald P. Taylor, Margaret A. Lindorfer
Blood (2024) Vol. 144, Iss. 2, pp. 137-144
Closed Access | Times Cited: 8
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Zhiwen Huang, Zachary Braunstein, Jun Chen, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 579-598
Open Access | Times Cited: 7
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 7
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer
Masayuki Nagahashi, Yasuo Miyoshi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3354-3354
Open Access | Times Cited: 6
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 6
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 6
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 5
Antibody-drug conjugates: the clinical development in gastric cancer
Yingze Zhu, Miao Zhou, Wenyue Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
HER2-Low Breast Cancer: Now and in the Future
Sora Kang, Sung‐Bae Kim
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 700-720
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top